/
Oncology
Other Solid Tumors
10
Pipeline Programs↗
8
Active Trials↗
13
Companies Involved↗
Other Solid Tumors is an early-stage landscape with 10 programs across 13 companies. The most active players are Betta Pharmaceuticals Co., Ltd., Allist Pharmaceuticals, Inc., Sichuan Baili Pharmaceutical Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 14
Phase 25
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
70%
Small molecule
7 of 10 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 10 pipeline programs.
Analysis
Trial Status
20
clinical trials
Recruiting5 · 25%
Completed4 · 20%
Unknown status4 · 20%
Active, not recruiting3 · 15%
Terminated2 · 10%
Withdrawn1 · 5%
Other1 · 5%
Clinical Trials
Trial Activity
20 trials
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment
Completed·—·Phase 1·NCT00544284·25 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)